PLRX vs. SPRY, ABVX, ZNTL, IMNM, DNTH, TNGX, ETNB, ARCT, EOLS, and OPK
Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include ARS Pharmaceuticals (SPRY), ABIVAX Société Anonyme (ABVX), Zentalis Pharmaceuticals (ZNTL), Immunome (IMNM), Dianthus Therapeutics (DNTH), Tango Therapeutics (TNGX), 89bio (ETNB), Arcturus Therapeutics (ARCT), Evolus (EOLS), and OPKO Health (OPK). These companies are all part of the "pharmaceutical preparations" industry.
Pliant Therapeutics (NASDAQ:PLRX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking.
97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 6.4% of Pliant Therapeutics shares are held by company insiders. Comparatively, 40.1% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Pliant Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.
Pliant Therapeutics received 54 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave ARS Pharmaceuticals an outperform vote while only 71.11% of users gave Pliant Therapeutics an outperform vote.
ARS Pharmaceuticals has lower revenue, but higher earnings than Pliant Therapeutics.
Pliant Therapeutics presently has a consensus price target of $45.38, indicating a potential upside of 187.91%. ARS Pharmaceuticals has a consensus price target of $18.50, indicating a potential upside of 101.31%. Given Pliant Therapeutics' higher possible upside, equities analysts clearly believe Pliant Therapeutics is more favorable than ARS Pharmaceuticals.
ARS Pharmaceuticals' return on equity of -21.14% beat Pliant Therapeutics' return on equity.
In the previous week, Pliant Therapeutics had 2 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 10 mentions for Pliant Therapeutics and 8 mentions for ARS Pharmaceuticals. Pliant Therapeutics' average media sentiment score of 0.29 beat ARS Pharmaceuticals' score of 0.26 indicating that Pliant Therapeutics is being referred to more favorably in the media.
Summary
Pliant Therapeutics beats ARS Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Pliant Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pliant Therapeutics Competitors List
Related Companies and Tools
